Document is current

CRISPR-engineered probiotics for targeted production of inosine as an immunomodulatory metabolite to enhance cancer immunotherapy response: A review

Crossref DOI link: https://doi.org/10.30574/wjarr.2026.29.1.0257

Published Online: 2026-01-31

Update policy: https://doi.org/10.30574/wjarr.ourcrossmarkpolicy